RxDoctor Payments DataLook up a doctor →

Andrew Gordon, MD

Neurology · Lake Barrington, ILNPI 1508898206

Payments from drug & device makers

$1,053,138in general payments, 2019–2025

Across 1,444 payments — averaging $729.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$476K
  • Argenx US, Inc.$215K
  • Guerbet LLC$83K
  • Regeneron$65K
  • UCB, Inc.$60K
  • Johnson & Johnson$45K
  • plus $109K from 43 others
$474in research payments, 2019–2025

Across 3 payments — averaging $157.86 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • AstraZeneca$474

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AstraZeneca(2 entities)580$476,452
Argenx US, Inc.259$215,007
Guerbet LLC6$82,638
Regeneron38$64,657
UCB, Inc.165$60,443
Johnson & Johnson(2 entities)38$45,320
Amgen(2 entities)50$41,054
Catalyst Pharmaceuticals, Inc.23$20,028
AbbVie(2 entities)102$20,001
Lundbeck LLC19$9,765
Biogen22$4,951
Takeda Pharmaceuticals U.S.A., Inc.21$4,941
Janssen Scientific Affairs, LLC4$2,386
Avion Pharmaceuticals1$1,760
Vertex1$400
Pfizer19$372
Novartis14$332
Lilly USA, LLC8$283
Inspire Medical Systems, Inc.3$214
EMD Serono, Inc.8$213
Baylis Medical Technologies Inc.1$167
Medtronic2$160
Alnylam Pharmaceuticals Inc.5$158
Acadia Pharmaceuticals Inc3$138
Grifols USA, LLC2$121
Sanofi1$112
Xeris Pharmaceuticals, Inc.5$108
Genentech USA, Inc.4$93
Abbott4$84
TG Therapeutics, Inc.4$84
Angiodynamics, Inc.1$66
Zyla Life Sciences, Inc.4$66
Bausch Health US, LLC3$52
Neurocrine Biosciences, Inc.2$51
Tanabe Pharma America, Inc.2$49
Currax Pharmaceuticals LLC3$47
Teva Pharmaceuticals USA, Inc.2$45
Eisai Inc.2$44
Biohaven Pharmaceutical Holding Company Ltd.2$38
Merz Pharmaceuticals, LLC1$36
SK Life Science, Inc.1$33
Bristol Myers Squibb1$33
Ipsen Biopharmaceuticals, Inc1$32
Amneal Pharmaceuticals LLC2$30
Acorda Therapeutics, Inc1$21
Amylyx Pharmaceuticals, Inc.1$18
Vertical Pharmaceuticals, LLC1$16
Philips North America LLC1$15
Hospira, Inc.1$2

How this compares

$1,053,138 in reported general payments places this provider in the 95th percentile of 790 neurology providers in Illinois.

See all neurology providers in Illinois →

Medicare billing

Part B allowed, 2024
$10,221,081
Medicare patients
468
Services billed
136,892

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other neurology in Lake Barrington

See the full list for Illinois →

Where these figures come from

Is this you, or does something look wrong? →